1. Locally Advanced NSCLC Implementing Innovation

2. Program Agenda

3. Current Standards in Locally Advanced (Stage III) NSCLC

4. International Standards for CRT for Locally Advanced (Stage 3) NSCLC

5. How Do We Plan Radiation?

6. ESMO Recommendations for Locoregional NSCLC

7. ESMO Recommendations continued

8. Overall Survival and Toxicity Associated With RT

9. Implementing New Data and Evolving Standards

10. Rationale Radiation + Immunotherapy

11. Pembrolizumab + Prior Radiation

12. PACIFIC Study

13. PFS in the ITT Population

14. Best Practices for Scanning After CRT

15. Rationale for Performing Scan Immediately Following CRT

16. Safety of Checkpoint Inhibitors

17. PACIFIC Trial: Adverse Events

18. Pneumonitis or Radiation Pneumonitis

19. Monitoring for imAEs

20. PACIFIC Trial: Discussion Topics

21. What Next?

22. Panel Discussion and Audience Question & Answer

23. PACIFIC PFS in the Intention-to-Treat Patients

24. How Do We Integrate New Data Into Practice?

25. Neoadjuvant Nivolumab Yielded Pathologic Responses in Resectable Lung Cancer

26. Discussion Topics

27. Concluding Remarks